Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The Icahn School of Medicine at The Mount Sinai Hospital announced the launch of an international clinical trial to evaluate the safety and efficacy of treating coronary stent patients with ticagrelor alone, rather than the current standard of care comprised of ticagrelor plus aspirin.
The TWILIGHT clinical trial, led by Roxana Mehran, MD, aims to study ticagrelor alone vs. ticagrelor plus aspirin in reducing the occurrence of bleeding and adverse events in up to 9,000 patients after percutaneous coronary intervention (PCI) with drug-eluting stents. After three months of dual anti-platelet therapy, patients will be randomly assigned to ticagrelor 90mg plus aspirin 81mg daily or ticagrelor plus placebo daily for 12 months. Bleeding events or adverse events such as heart attack, stroke, and mortality will be tracked.
RELATED: New Brilinta Indication Accepted for Priority Review
Over 100 sites across the United States, Canada, Europe, South America, and Asia will enroll patients in the study. Individuals are eligible if they are aged ≥18, have undergone successful PCI with at least one drug-eluting stent, and have been discharged on ticagrelor and aspirin for three months.
For more information visit MountSinai.org.
